30 Participants Needed

Dietary Intervention for Breast Cancer Risk Reduction

(LIN-BRiCK Trial)

TO
Overseen ByThe Ohio State University Comprehensive Cancer Center
Age: 18+
Sex: Female
Trial Phase: Academic
Sponsor: Ohio State University Comprehensive Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to determine if the Low-Insulinemic Dietary Intervention can lower breast cancer risk in high-risk women. The diet emphasizes foods that cause a low insulin response, including fruits, vegetables, whole grains, and plant-based proteins. Post-menopausal women with a BMI between 25 and 35 who are receiving care at a specific cancer center may be suitable candidates. Participants will attend nutrition education sessions, receive counseling, and track their activity to assess the diet's effectiveness. As an unphased trial, this study provides a unique opportunity to contribute to groundbreaking research that could lead to new dietary recommendations for breast cancer prevention.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, it mentions that changes in anti-hyperglycemic or lipid-lowering medications should be avoided unless necessary. You can continue using endocrine therapy, but you cannot change the dose or schedule during the study.

What prior data suggests that this dietary intervention is safe for reducing breast cancer risk?

Research has shown that diets lowering the body's insulin response can be safe and beneficial. Studies have found that consuming foods with a low glycemic index (GI) can reduce the risk of several types of cancer. These foods digest slowly, helping to maintain stable blood sugar and insulin levels. One study found that reducing the insulin-related effects of a diet may lower the risk of breast cancer.

Importantly, no evidence suggests that this type of diet increases breast cancer risk. Instead, it may improve health by regulating blood sugar and reducing the risk of heart disease. So far, this dietary approach appears safe and well-tolerated.12345

Why are researchers excited about this trial?

Researchers are excited about the Low-Insulinemic Dietary Intervention for reducing breast cancer risk because it offers a non-pharmacological approach to prevention. Unlike typical treatments that focus on medication, this intervention emphasizes dietary changes that potentially lower insulin levels, which may be linked to cancer risk reduction. This approach is unique because it combines nutrition education, motivational interviewing, and practical cooking demonstrations, empowering participants to make sustainable lifestyle changes. By focusing on diet and lifestyle, this method could provide a side-effect-free option for those looking to proactively manage their breast cancer risk.

What evidence suggests that this dietary intervention could be effective for reducing breast cancer risk?

Research has shown that eating a diet that lowers the body's insulin response might help reduce the risk of breast cancer. This trial will test a low-insulinemic dietary intervention, focusing on foods with these positive effects, such as plant-based proteins, fruits, vegetables, whole grains, and fiber. One study suggested that changing a diet to lower its insulin response can decrease breast cancer risk. Another study found that women who consumed foods that significantly raised their blood sugar levels had a higher risk of dying from breast cancer. Additionally, diets that help prevent insulin resistance and diabetes might also lower breast cancer risk.12678

Who Is on the Research Team?

FK

Fred K Tabung, PhD, MSPH

Principal Investigator

Ohio State University Comprehensive Cancer Center

Are You a Good Fit for This Trial?

This trial is for high-risk women who may benefit from a new diet aimed at reducing breast cancer risk. The diet focuses on lowering blood insulin levels and includes plant proteins, fruits, vegetables, whole grains, and dietary fiber while being low in animal proteins and fats.

Inclusion Criteria

High risk for breast cancer at the discretion of the physician, using standard definitions such as a Gail 5-year risk of ≥ 2% or Tyrer Cuzick version (v) 8.0 10-year risk of ≥ 5%
Currently established care or previously seen at the Ohio State University Comprehensive Cancer Center (OSUCCC) Stefanie Spielman Comprehensive Breast Center (SSCBC) high risk breast clinic
I am a cis-gender woman, 45 or older, or post-menopausal.
See 2 more

Exclusion Criteria

Currently on special diet for known metabolic or gastrointestinal disease, or planning to start a specific dietary regimen such as vegetarian, vegan, ketogenic, low-fat diets, etc
Pregnant, trying to get pregnant, or nursing
Any condition which in the investigator's opinion deems the subject an unsuitable candidate to participate in this study
See 12 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Dietary Intervention

Participants receive the low-EDIH dietary pattern intervention consisting of 6 group nutrition education sessions and 3 individual counseling sessions.

11 weeks
6 group sessions (in-person), 3 individual sessions (in-person or virtual)

Follow-up

Participants are monitored for safety and effectiveness after the dietary intervention

1 week
1 visit (in-person or virtual)

What Are the Treatments Tested in This Trial?

Interventions

  • Low-Insulinemic Dietary Intervention
Trial Overview The study evaluates the feasibility of adhering to a low-insulinemic diet that differs from typical American diets. It involves using medical devices for monitoring, motivational interviews to support adherence, biospecimen collection for analysis, nutritional assessments, and questionnaires.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: Prevention (Low-EDIH dietary pattern intervention)Experimental Treatment6 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Ohio State University Comprehensive Cancer Center

Lead Sponsor

Trials
350
Recruited
295,000+

American Cancer Society, Inc.

Collaborator

Trials
237
Recruited
110,000+

Published Research Related to This Trial

A systematic review of 53 cohort studies involving over 100,000 cancer cases found a weak association between dietary glycemic index (GI) and glycemic load (GL) with the risk of diabetes-related cancers, indicating that high GI/GL diets may not significantly increase cancer risk.
Most studies showed no significant link between insulin index (II) or insulin load (IL) and cancer risk, with only one study reporting a positive association for IL in endometrial cancer, suggesting that more research is needed to clarify these relationships.
Dietary glycemic index, glycemic load, insulin index, insulin load and risk of diabetes-related cancers: A systematic review of cohort studies.Hatami Marbini, M., Amiri, F., Sajadi Hezaveh, Z.[2021]
In a preclinical study using a rat model, a low glycemic load diet significantly reduced breast cancer incidence (23.3% vs. 50.0%) and tumor burden compared to a high glycemic load diet, suggesting a protective effect against cancer development.
The protective effect of the low glycemic load diet was linked to changes in cell growth regulation markers, but this effect was diminished when diets were adjusted to isolate specific components like resistant starch, indicating that other dietary factors also play a role in cancer risk.
Effect of low or high glycemic load diets on experimentally induced mammary carcinogenesis in rats.Thompson, HJ., Neuhouser, ML., Lampe, JW., et al.[2018]
Low glycaemic-index diets can lead to rapid weight loss and improvements in key metabolic markers, including reduced fasting glucose and insulin levels, lower triglycerides, and better blood pressure.
While these short-term benefits are promising, the long-term effects of low glycaemic-index diets on metabolic diseases and cardiovascular risk still require further controlled studies.
Metabolic effects of low glycaemic index diets.Radulian, G., Rusu, E., Dragomir, A., et al.[2023]

Citations

Low glycemic index diet, exercise and vitamin D to reduce ...Low GI foods lower the glycemic and insulinemic potential of the diet and have been shown to reduce the risk of several cancers particularly ...
Association between glycemic index and glycemic load of ...Conclusions: Dietary GL was positively associated with increased BC risk in the total sample. In premenopausal women, higher intake of insoluble ...
Insulinemic potential of diet and risk of total and subtypes ...Our findings suggest that dietary modifications to reduce insulinemic potential may reduce the risk of breast cancer.
Diet and Prognosis in Women with Breast CancerThe researchers found that women in the highest quintile of glycemic load had a 31% higher risk of breast cancer–specific mortality and a 26% ...
Consumption of “Diabetes Risk Reduction Diet” and Odds ...Therefore, it seems that following a diet to reduce risk of insulin resistance and diabetes might also reduce the risk of breast cancer.
Dietary Approach of Patients with Hormone-Related ...High glycemic index and glycemic load diets are associated with cancer development and worse prognosis, partially explained by the adverse effects on insulin ...
Dietary Glycemic Load and Breast Cancer Risk in the ...We found no evidence of increased breast cancer risk in the cohort as a whole with either increasing dietary GL or increasing overall GI.
Glycemic index, glycemic load and glycemic response: An ...In these studies, a low GI diet significantly improved glycemic control and decreased CVD risk factors in T2DM and a low GL diet was found to improve glycemic ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security